歌礼制药宣布ASC30美国II期研究首例受试者给药,口服小分子GLP-1R激动剂瞄准糖尿病治疗

美股速递
Jan 26

歌礼制药-B近日披露,其研发的口服小分子GLP-1受体激动剂ASC30在美国开展的II期临床研究中,已完成首例受试者给药。该项研究设计周期为13周,旨在评估ASC30针对糖尿病治疗的安全性与有效性。

作为创新疗法,ASC30通过激活GLP-1受体路径调控血糖水平,其小分子口服剂型有望突破现有注射类药物的使用限制。此次美国II期研究的启动,标志着该药物全球临床开发进入新阶段。

若后续临床试验验证其疗效与安全性,ASC30或将为糖尿病治疗领域提供更便捷的用药选择。目前,全球糖尿病药物市场持续扩容,GLP-1靶点疗法竞争日趋激烈,歌礼制药的研发进展备受行业关注。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10